# A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer

> **NCT06979908** · PHASE2 · RECRUITING · sponsor: **The First Hospital of Jilin University** · enrollment: 46 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Fruquintinib+Sintilimab+Chidamide

## Key facts

- **NCT ID:** NCT06979908
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-22
- **Primary completion:** 2026-07-22
- **Final completion:** 2027-01-22
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06979908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06979908, "A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06979908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*